High Blood Pressure Clinical Trial
Official title:
Effect of Vitamin D Supplementation on Blood Pressure in Elderly People
The prevalence and incidence of cardiovascular disease (such as Hypertension) increases exponentially with age (McDermott, 2007;) These diseases account for 30% of the global mortality (WHO, 2011). Vitamin D (VD) insufficiency affects as many as half of otherwise healthy adults in developed countries (Holick, 2007). VD is implicated in the control of blood pressure (BP) through inhibition of the renin-angiotensin system (Yamshchikov, 2009), although the role of VD supplementation for prevention and treatment of the HTA is controversial.The purpose of this study was to investigate if VD supplement in elderly people reduces the levels of BP.
Study population Adults aged ≥ 60 years with essential hypertension were recruited through
nursing homes and physical activity groups in the state of Colima, México. 45 subjects were
assessed for eligibility at our out-patient clinic. We excluded subjects with impaired renal
or hepatic function; also subjects who had been treated with vitamin D within the last three
months.
None were on hormone replacement therapy, but we included subjects on anti-hypertensive for
more than 10 years and the dosages were unchanged during the study. Before randomization, two
subjects withdrew the informed consent because of personal reasons, and two subjects were
excluded due to the diagnosis of severe hypertension.
Design The design was a double-blind, placebo controlled randomized clinical trial. The
participants were randomly assigned using a computer-generated randomization code into two
groups: group 1 (calcitriol group)with 22 subjects whom were enrolled for 6 weeks of
treatment with a daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg
each) and group 2 with 23 subjects (control group) whom received a similar placebo tablet for
also 6 weeks.
During treatment, nine subjects (20%) left the trial due to personal reasons. All patients
provided written informed consent. The study was conducted in accordance with the Declaration
of Helsinki II and the guidance on Good Clinical Practice (GCP). Approval was obtained from
the bioethics committee of the Faculty of Medicine from the University of Colima
(FM014/2012).
Measurement At the screening visit prior to randomization, subjects had a routine clinical
examination and data concerning medical history. BP was measured 3 consecutive days at the
same time, using a kit integrated aneroid sphygmomanometer with stethoscope (medimetrics
5769) with the patient seated and with at least 5 min rest. The subjects with average BP
>140/90 mm Hg were included in the study.
Once enrolled in the study groups, anthropometrics measurements were collected. The
measurements performed were weight and height with light clothing and no shoes, and the
indicator body mass index (kg/m2) was calculated. For the determination of serum 25(OH)D,two
blood samples were collected in the morning after an overnight fast of minimum 8 h on the day
of the randomization and at the end of the study.
The patients attended control visits every week for safety measures, adverse event
registration and assessment of compliance.Returned pills were counted at each visit, and
compliance was calculated as the percentage of used pills compared to the expected number.
Biochemistry Serum 25(OH)D concentration were measured with the use of competitive
enzyme-linked immunosorbent assay (ELISA: immunodiagnostic, Bernheim, Germany) after
solid-phase extraction (reference range: 17-53 pg/mL). The intra- and interassay CVs for the
2 Vitamin D metabolites were <7,0% and 9,0%, respectively.
Statistical Analysis The data were analyzed with the SPSS version 21. The variables studied
were described as frequencies, percentages and as median (interquartile range); inferential
statistics were performed with non parametric tests (Mann Whitney and related sample Wilcoxon
test), and correlations between variables were analyzed by bivariate correlation analysis by
Pearson's correlation. Statistical significance was set at a p value < 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03812614 -
Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support
|
N/A | |
Completed |
NCT03650166 -
High BP and Home Monitoring Experience (HoME) Study
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT01622400 -
Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk
|
N/A | |
Completed |
NCT00659672 -
Effect of Whey Protein on Blood Pressure
|
N/A | |
Completed |
NCT00473681 -
Intervention Study to Control High Blood Pressure for Korean American
|
N/A | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05526092 -
OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals
|
N/A | |
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Recruiting |
NCT03753204 -
Salt-Sensitivity and Immunity Cell Activation
|
Phase 1/Phase 2 | |
Completed |
NCT04479384 -
The Immediate Effect of an Osteopathic Manual Treatment on Blood Pressure in Adults With Hypertension - a Pilot Study.
|
N/A | |
Not yet recruiting |
NCT04064281 -
The Healthy Cantonese Diet on Cardiometabolic Syndrome
|
N/A | |
Completed |
NCT04082819 -
MediBeat - HeartBeat Observation Trial
|
N/A | |
Completed |
NCT03555344 -
Effect of Mantra on Hypertensive Patients
|
N/A | |
Withdrawn |
NCT03319823 -
Treating Nocturnal Hypertension and Nocturia in African American Men
|
Phase 4 | |
Completed |
NCT00689819 -
Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
|
N/A | |
Completed |
NCT00417170 -
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
|
Phase 2 | |
Completed |
NCT00130156 -
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
|
Phase 4 | |
Completed |
NCT05808556 -
Sticker Pad Containing Essential Oil in Volunteer With High Blood Pressure
|
N/A | |
Recruiting |
NCT05321368 -
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
|
N/A |